Incyte

Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993.

Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi.

As of 2014 the company was developing an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly called baricitinib. As of August 2016^[update] 31 clinical trials had been registered for baricitinib of which 24 had completed, and 4 of 6 phase 3 trials had completed.

As of 2016 epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor, is in development for various cancers. The ECHO-202 study (NCT02178722) is evaluating epacadostat in combination with Keytruda (pembrolizumab)*, Merck’s anti-PD-1 therapy. In 2017 the phase III KEYNOTE-252/ECHO-301 trial reported good results for epacadostat (INCB024360) in some types of melanoma.

Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is in Phase II clinical trial as monotherapy in patients with advanced .

In 2014, Incyte named Hervé Hoppenot president and CEO. Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003.

In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.